Ultime notizie per GDS Holdings (NASDAQ:GDS) Azioni

GDS HOLDINGS LTD - ADR

GDS Holdings

GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.

GDS Holdings Limited - American Depositary Shares

GDS Holdings Ltd

GLOBAL DIGITAL SLTNS INC by Global Digital Solutions, Inc.

Global Digital Solutions Inc

Nevada Zinc Corp

GOLDENSTONE ACQ LTD by Goldenstone Acquisition Limited

Goldenstone Acquisition Ltd

GOLDENSTONE ACQUISITION LTD RT

Goldenstone Acquisition Ltd Units (1 Ord , 1 War & 1 Rts)

Goldenstone Acquisition Ltd Warrants (15/07/2026)

Barclays analyst Matthew Bouley maintains Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) with a Overweight and lowers the price target from $90 to $70.

News

Price Target

Analyst Ratings

TMHC

Barclays Maintains Overweight on Taylor Morrison Home, Lowers Price Target to $70

Barclays analyst Matthew Bouley maintains SiteOne Landscape Supply (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NYSE">SITE</a>) with a Underweight and lowers the price target from $120 to $106.

SITE

Barclays Maintains Underweight on SiteOne Landscape Supply, Lowers Price Target to $106

<a href="https://www.youtube.com/live/Z1ZTlURVm94?si=-6lmaGc44N_4EOnQ" title="https://www.youtube.com/live/Z1ZTlURVm94?si=-6lmaGc44N_4EOnQ">https://www.youtube.com/live/Z1ZTlURVm94?si=-6lmaGc44N_4EOnQ</a>

Macro Economic Events

Politics

Economics

General

Fed's Daly Says Fed Policy In A Very Good Place; Says Modestly Restrictive; Says We've Time To Tread Slowly, Carefully On Policy

Barclays analyst Matthew Bouley maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Equal-Weight and lowers the price target from $117 to $100.

Barclays Maintains Equal-Weight on PulteGroup, Lowers Price Target to $100

Barclays analyst Matthew Bouley maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Overweight and lowers the price target from $215 to $179.

Barclays Maintains Overweight on Owens-Corning, Lowers Price Target to $179

Spruce Point Capital Management&nbsp;has announced a short position against Monster Beverage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) as the short seller sees <a href="https://www.benzinga.com/quote/MNST">25% to 40% downside risk</a>.
What To Know: After conducting a forensic financial and accounting review, <a href="https://www.benzinga.com/topic/short-sellers">short seller</a> Spruce Point raised concerns about the sustainability of Monster&#8217;s recent financial performance and the accuracy of its accounting and financial reporting in a new short report released Tuesday. 
&#8220;Changing consumer preferences, an evolving regulatory landscape, and pressures to reduce government supported programs for unhealthy foods leaves Monster vulnerable to escalating threats,&#8221; the short seller said.
&#8220;We believe Monster is likely aware of these challenges and is acting in a manner to combat these issues. However, we also believe that Monster may be taking aggressive and/or non-transparent actions that are not in the best interests of investors.&#8221;
Benzinga has reached out to Monster Beverage for comment on the report. 
Spruce Point believes Monster Beverage shares are fully valued and offer poor risk/reward from current levels. The short seller noted that insiders have been accelerating their pace of stock sales and more than 50% of analysts don&#8217;t have a &#8220;Buy&#8221; rating on the stock.
Monster also trades with an &#8220;irrational&#8221; premium compared to Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) despite being highly dependent on the company for distribution, the short seller said. Monster has a price-to-earnings ratio of approximately 30.8, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Meanwhile, Coca-Cola trades with a price-to-earnings ratio of approximately 20. 
Furthermore, Spruce Point alleged that Monster&#8217;s relationship with Coke is &#8220;not healthy&#8221; and a potential takeover deal is not in the cards. The short seller said it uncovered evidence of a financial strain between the two companies starting in 2022. 
Check This Out: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44697600/stocks-rebound-chipmakers-soar-on-trade-deal-hopes-bitcoin-lags-whats-driving-markets-tuesday#google_vignette">Stocks Rebound, Chipmakers Soar On Trade Deal Hopes, Bitcoin Lags: What&#8217;s Driving Markets Tuesday?</a>
Spruce Point also said it takes issue with how Monster is reporting sales for its Tour Water brand. Although it&#8217;s not an energy drink product, the company reported its revenue in the Monster Energy Drinks segment, which could &#8220;potentially be a lever to inflate energy drink organic sales.&#8221;
&#8220;Moreover, Monster says it is distributed through the Alcohol Brands segment, which casts further doubt on the soundness of its revenue recognition choice,&#8221; the short seller said. 
Spruce Point went on to raise concerns around margins on sales through Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), production inefficiencies, increasing competition and social media brand stagnation. 
Spruce Point issued a &#8220;Strong Sell&#8221; opinion on Monster shares as the short seller expects Monster to underperform the food and beverage industry along with the broader equity market moving forward. 
MNST Price Action: <a href="http://benzinga.com/quote/mnst">Monster Beverage shares</a> were down 2.6% at $55.60 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44696168/apple-is-a-buying-opportunity-again-as-key-valuation-level-flashes-green-bank-of-america-says">Apple Is A &#8216;Buying Opportunity&#8217; Again As Key Valuation Level Flashes Green, Bank Of America Says</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/nawawi+mohamed">kiraziku2u</a>/Shutterstock.

Short Sellers

Short Ideas

Trading Ideas

AMZN

MNST

Short Seller Sees 25% To 40% Downside In Monster Beverage Shares: 'Vulnerable To Escalating Threats'

WIIM

ACDC

CLMT

CSAN

FANG

KLXE

Shares of energy companies are trading lower possibly amid ongoing weakness after crude levels dropped to 2021 levels following OPEC+'s decision to accelerate production hikes. Also, the industry may be declining due to global tensions related to US-China retaliatory tariffs.

Global

Federal Reserve

Fed's Daly Says CEOs Feel Uncertain; Says Businesses Are Optimistic About Growth; Says People Move Through Uncertainty, There's Resilience And Agility; Says  A Little Concerned Inflation May Pick Back Up From Tariffs; Says Uncertainty We Have Now Can Be Worked Through; Says Important To Stay Steady, Think About Net Effect Of Administration's Slate Of Changes; Says Don't Have Complete Clarity On Tariffs

Barclays analyst Matthew Bouley maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Equal-Weight and lowers the price target from $125 to $115.

Barclays Maintains Equal-Weight on Mohawk Industries, Lowers Price Target to $115

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and lowers the price target from $87 to $75.

Barclays Maintains Overweight on Masco, Lowers Price Target to $75

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension&nbsp;(OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (gMG)</a>.
Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living)&nbsp;and QMG (quantifies disease severity)&nbsp;scores over 84 weeks with sustained reductions <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678645/johnson-johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstrating-long-t" rel="noreferrer noopener">in total immunoglobulin G (IgG)</a>.
Nipocalimab demonstrated a mean change in MG-ADL of -5.64 (p&lt;0.001) after 60 weeks in the OLE for study participants receiving nipocalimab and SOC, and -6.01 (p&lt;0.001) mean change&nbsp;for study participants who transitioned from placebo and SOC to nipocalimab and SOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651117/johnson-johnsons-tremfya-shows-efficacy-across-multiple-domains-in-late-stage-psoriatic-arthritis-study" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study</a>
In the antibody-positive population, 45%&nbsp;of patients receiving steroids at the OLE baseline were able to decrease or discontinue steroids at the time of this data cut by more than half of the baseline dose.
<ul>
<li>Among these patients, the mean dose of prednisone decreased from 23 to 10&nbsp;mg daily.</li>
</ul>
Nipocalimab had a consistent and tolerable safety profile throughout the OLE phase.
Additional findings from the Phase 3 Vivacity-MG3 study indicate that patients treated with nipocalimab plus SOC achieved statistically significant improvements in their QMG score by -4.9 versus placebo plus SOC (p&lt;0.001) over weeks 22 and 24.
Patients in the nipocalimab plus SOC treatment group were four times more likely to sustain symptom improvement at 20 weeks than the placebo plus SOC group, as measured by a three- or greater-point improvement on the QMG score.
Results show significantly more patients treated with nipocalimab (36.4%) versus placebo (10.5%, p&lt;0.001) spent greater than 75% of the study duration, demonstrating improvements in the QMG score.
A reduction of more than three points in the QMG score indicates a decrease in the severity of the patient&#8217;s symptoms due to improvements in muscle strength, allowing patients to carry out important daily activities such as swallowing and chewing.
Price Action: JNJ stock is down 0.21% at $150.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech" target="_blank" rel="noreferrer noopener">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

Barclays analyst Matthew Bouley maintains Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) with a Equal-Weight and lowers the price target from $7 to $6.

LSEA

Barclays Maintains Equal-Weight on Landsea Homes, Lowers Price Target to $6

Barclays analyst Matthew Bouley maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Equal-Weight and lowers the price target from $6 to $5.

JELD

Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $5

Canada Says It's Already Announced 25% Counter-tariffs Against Some US-Made Autos, Will Go Into Effect April 9; Says The Tariffs Will Remain In Place Until U.S. Eliminates Its Tariffs Against The Canadian Auto Sector- Reuters

Barclays analyst Matthew Bouley maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Equal-Weight and lowers the price target from $11 to $8.

HLMN

Barclays Maintains Equal-Weight on Hillman Solns, Lowers Price Target to $8

Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (MG)</a>.
MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction.
As&nbsp;previously announced, the trial met its primary endpoint and demonstrated a safety profile supporting outpatient <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39594800/cartesians-autoimmune-disorder-candidate-hits-primary-goal-in-mid-stage-study-announces-equity-ra" rel="noreferrer noopener">administration of Descartes-08</a>.
As of a March 31, 2025, cutoff date, 12 out of 15 participants who received Descartes-08 in the primary efficacy dataset completed <a href="https://www.benzinga.com/pressreleases/25/04/g44681067/cartesian-therapeutics-descartes-08-observed-to-provide-deep-and-sustained-benefits-through-month-" target="_blank" rel="noreferrer noopener">their Month 12 follow-up assessments</a>.
Participants treated with Descartes-08 were observed to have deep responses following initial treatment and sustained symptom improvement, with an average MG Activities of Daily Living (MG-ADL, score to assess impact on daily functions) reduction of 5.5 (±1.1) at Month 4 and 4.8 (±1.4) at Month 12.
<ul>
<li>Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0±2.1).</li>
<li>33% (4/12) of participants achieved minimum symptom expression (MSE), defined as an MG-ADL score of 0 or 1, at month 6, all of whom maintained MSE through month 12.</li>
<li>83% (10/12) of evaluable participants maintained a clinically meaningful response through month 12.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44694287/pacira-settles-patent-dispute-over-exparel-with-fresenius-and-others-delays-pain-med-exparels-generics-entry-until-2030-stock-jumps" rel="noreferrer noopener">Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med&#8217; Generics Entry Until 2030, Stock Jumps</a>
The subset of participants who had not been exposed to prior biologic therapies exhibited a deepening of responses throughout the year, with an average MG-ADL reduction of 6.6 (±1.5) at Month 4 and 7.1 (±1.9) at month 12.
<ul>
<li>The participants were observed to have an average QMG reduction of 5.9 (±2.4) points at month 4, which deepened through month 12 (9.4±2.6).</li>
<li>57% (4/7) of these participants were observed to achieve MSE at month 6, which was maintained through month 12.</li>
<li>100% (7/7) of these participants were observed to maintain at least a clinically meaningful response through month 12.</li>
</ul>
Consistent with previously reported data, Descartes-08 was observed to be well-tolerated across the safety dataset through month 12 (n=12), and adverse events were transient and mostly mild, with no new adverse events reported in the 12-month follow-up data.
Cartesian remains on track to commence the Phase 3 AURORA trial of Descartes-08 in MG in the second quarter of 2025.
RNAC Price Action: Cartesian Therapeutics stock is down 3.56% at $9.75 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44691525/wd-40-margins-expand-in-q2-raises-2025-profit-outlook" target="_blank" rel="noreferrer noopener">WD-40 Margins Expand In Q2, Raises 2025 Profit Outlook</a></li>
</ul>
Photo: Shutterstock

RNAC

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients

Barclays analyst Matthew Bouley maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Overweight and lowers the price target from $79 to $68.

FBIN

Barclays Maintains Overweight on Fortune Brands, Lowers Price Target to $68

Barclays analyst Matthew Bouley maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Equal-Weight and lowers the price target from $145 to $120.

Barclays Maintains Equal-Weight on D.R. Horton, Lowers Price Target to $120

Barclays analyst Matthew Bouley maintains Champion Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) with a Equal-Weight and lowers the price target from $106 to $97.

Barclays Maintains Equal-Weight on Champion Homes, Lowers Price Target to $97

CORRECTION: Retail Stocks Are Lower

Earnings

Press Releases

GDS Holdings Limited Reports Second Quarter 2024 Results

GDS Releases 2023 ESG Report

GDS Announces US$1.0 Billion Equity Raise By Its International Affiliate Led By Prestigious New US Investors

Legal

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of GDS Holdings Limited Publicly-Traded American Depositary Shares - GDS

GDS to Report Third Quarter 2024 Financial Results Before the Open of the U.S. Market on November 19, 2024

The Rosen Law Firm, P.A. Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of GDS Holdings Limited Publicly-Traded American Depositary Shares - GDS

Comments

GDS Holdings

Notizie

Ultime notizie per GDS Holdings (NASDAQ:GDS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO